Escitalopram
Escitalopram has been studied in 27 papers since 2016: 8 trials and 6 observational studies in people, 2 in animals, 10 reviews; 13 in the past year. It is an approved medicine. The newest paper, Oct 30, 2026: “Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis”.
2 new papers in 30 daysSee all 33 papers on escitalopram
At a glance
The findings reach people, from one lab or study. 8 independent labs in 5 countries; 192 trials, none about aging, 79 with no results posted.
“Escitalopram significantly reduced both anxiety and vasomotor symptom severity in perimenopausal women”
None of its findings points the other way.
- 8 independent labs in 5 countries
- 192 trials, none about aging, 79 with no results posted
- Funders: Fudan University and others
- 26 of 192 trials sponsored by its developers
- Human trial8
- Humans6
- Animals1
- Model organisms1
Studies in people
2 studies gave escitalopram to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases anxiety down: Decreases vasomotor symptoms | Trial12 weeks | 346 peopleWomen30–75 yearsPostmenopausal women; Midlife adults; Older adults; perimenopausal women with vasomotor symptoms and anxiety | Journal of University Medical & Dental College, Apr 11, 2026 |
down: Decreases hot flashes down: Decreases Menopause Rating Scale | Randomized trialten weeks | 26 peopleWomenIn patients with breast cancer | Journal of psychosomatic obstetrics and gynaecology, Oct 14, 2021 |
What did studies of escitalopram find?
14Studies of escitalopram measured 14 outcomes, among them vasomotor symptoms, vasomotor symptoms and anxiety.
Vasomotor symptoms
downin humans1
1 study
Vasomotor symptoms
downin humans1
Escitalopram decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -1.08, 95% CI -1.80 to -0.37).
“Five interventions were significantly more effective than placebo: escitalopram (SMD -1.08, 95% CI -1.80 to -0.37)”
Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales
Frontiers in pharmacology
Vasomotor symptoms
downin humans1
1 study
Vasomotor symptoms
downin humans1
Escitalopram decreases vasomotor symptoms in humans (perimenopausal women with vasomotor symptoms and anxiety).
“Escitalopram significantly reduced both anxiety and vasomotor symptom severity in perimenopausal women”
Human trialperimenopausal women with vasomotor symptoms and anxiety10 mg daily12 weeksfemalesn = 346
Journal of University Medical & Dental College
Anxiety
downin humans1
1 study
Anxiety
downin humans1
Escitalopram decreases anxiety in humans (perimenopausal women with vasomotor symptoms and anxiety).
“Escitalopram significantly reduced both anxiety and vasomotor symptom severity in perimenopausal women”
Human trialperimenopausal women with vasomotor symptoms and anxiety10 mg daily12 weeksfemalesn = 346
Journal of University Medical & Dental College
Depressive symptoms
downin humans1
1 study
Depressive symptoms
downin humans1
Escitalopram decreases depressive symptoms in patients with major depressive disorder.
“Escitalopram and venlafaxine effectively manage depressive symptoms and vasomotor instability in patients with major depressive disorder.”
Reviewin patients with major depressive disorderfemales
FIGO best practice recommendations for the mental health of women at menopausal age
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Cellular senescence
upin human cells1
1 study
Cellular senescence
upin human cells1
Escitalopram induces cellular senescence in human cells.
“in human BJ fibroblasts, escitalopram triggered premature cellular senescence”
CellsBJ fibroblasts
Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway
GeroScience
Autophagy
downin worms1
1 study
Autophagy
downin worms1
Escitalopram inhibits autophagy in worms.
“leading to the subsequent suppression of autophagy.”
Model organisms
Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway
GeroScience
Healthspan
downin worms1
1 study
Healthspan
downin worms1
Escitalopram impairs healthspan in worms.
“escitalopram administration at juvenile, young, or old adult stages significantly shortens lifespan and impairs healthspan in Caenorhabditis elegans.”
Model organisms
Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway
GeroScience
Lifespan
downin worms1
1 study
Lifespan
downin worms1
Escitalopram shortens lifespan in worms.
“escitalopram administration at juvenile, young, or old adult stages significantly shortens lifespan”
Model organisms
Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway
GeroScience
Depression
downin humans1
1 study
Depression
downin humans1
Escitalopram decreases depression in humans (post-hip fracture rehabilitation in skilled nursing facility).
“Instead of doxepin, a highly anticholinergic antidepressant, the resident is effectively transitioned to escitalopram, resulting in a stable mood.”
Human trialpost-hip fracture rehabilitation in skilled nursing facilityfemales
The Pharmacist's Role in Age-Friendly Mobility
The Senior care pharmacist
Menopause Rating Scale
downin humans1
1 study
Menopause Rating Scale
downin humans1
Escitalopram decreases Menopause Rating Scale in patients with breast cancer.
“They could both decrease the total score of MRS.”
Human trialin patients with breast cancer10 mgten weeksfemalesn = 26
Journal of psychosomatic obstetrics and gynaecology
Hot flashes
downin humans1
1 study
Hot flashes
downin humans1
Escitalopram decreases hot flashes in patients with breast cancer.
“PMRT and escitalopram could effectively decrease number and duration of diurnal and nocturnal HFs in patients with breast cancer”
Human trialin patients with breast cancer10 mgten weeksfemalesn = 26
Journal of psychosomatic obstetrics and gynaecology
Geriatric depression
downin humans1
1 study
Geriatric depression
downin humans1
Escitalopram decreases geriatric depression in humans.
“Both groups improved significantly on depression severity (HAM-D score), but not on cognitive outcomes at six months.”
Human trial6 months
Memantine can protect against inflammation-based cognitive decline in geriatric depression
Brain, behavior, & immunity - health
All 14Fewer
What is escitalopram linked with?
2Studies link escitalopram with 2 measures: mortality and hemorrhagic stroke.
Mortality
upin humans1RR 1.09
1 study
Mortality
upin humans1RR 1.09
Escitalopram is associated with mortality in humans (new prescription compared with sertraline or paroxetine) (2.86% vs. 2.63%; RR 1.09, 95% CI 1.01 to 1.18).
“but was associated with a higher risk of mortality (2.86% vs. 2.63%, RR 1.09, 95% CI 1.01 to 1.18).”
Humansnew prescription compared with sertraline or paroxetine90 days
Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study
PloS one
Hemorrhagic stroke
upin humans1RR 1.33
1 study
Hemorrhagic stroke
upin humans1RR 1.33
Escitalopram is linked with a higher risk of hemorrhagic stroke in humans following traumatic brain injury (RR 1.33, 95% CI 1.02–1.74).
“escitalopram (RR, 1.33; 95% CI, 1.02-1.74) and sertraline (RR, 1.46; 95% CI, 1.10-1.94) were associated with an increase in the risk of hemorrhagic stroke.”
Humansfollowing traumatic brain injury
Risk of Stroke Among Older Medicare Antidepressant Users With Traumatic Brain Injury
The Journal of head trauma rehabilitation
Has escitalopram been tested in people?
0 of 192 about agingYes: 8 trials and 6 observational studies in people have been published, and 192 trials are registered.
Approved
Aug 14, 2002Depressive Disorder, Major, Generalized Anxiety Disorder
Aug 29, 2002
Nov 27, 2002Discontinued
Aug 29, 2025Depressive Disorder, Major, Generalized Anxiety Disorder
Repurposing
Phase 4Completed6 trials
Phase 4Completed5 trials
Phase 4Results posted2 trials
Phase 4Results posted69 trials
Phase 4Status unknown4 trials
Phase 4Completed2 trials
40 of 82Fewer
In trials
Psychological Well-Being
Phase 4Terminated2 trials
Behavior
Phase 2Results posted1 trial
Self-injurious behavior
Phase 2Terminated1 trial
Stopped
NCT00660062TerminatedMajor depressive disorder
Slow inclusion
NCT01244724TerminatedMajor depressive disorder
Unable to recruit targeted #
NCT01787240TerminatedMajor depressive disorder
Recruitment difficulties
NCT03993457TerminatedMajor depressive disorder
terminated during COVID due to inability to see participants in person.
NCT04697693TerminatedMajor depressive disorder
Unable to recruit participants in a timely fashion due to COVID pandemic
NCT00464191TerminatedBipolar disorder
The study has been terminated because too few patients have been recruited
All 11Fewer
Trial sponsors
Company6 trialsPhase 42,711 people
Company5 trialsPhase 4876 people
Company3 trialsPhase 41,550 people
Company3 trialsPhase 4804 people
Company1 trialPhase 4273 people
HolsboerMaschmeyer NeuroChemie
Company1 trialPhase 480 people
Company5 trialsPhase 33,802 people
Company2 trialsPhase 31,153 people
Funding
1 grant since 2019São Paulo Research Foundation